TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06298877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty and Quality of Life evaluation
Description: Frailty and Quality of Life evaluation after surgery
Study: NCT05960955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV infusion,Specified dose on specified days
Study: NCT05037097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021
Description: Dose 1
Study: NCT04758000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI \> 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified.
Study: NCT04837677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT1419
Description: PRT1419 will be administered by intravenous infusion
Study: NCT04508543

Intervention type: OTHER
Intervention: Non-verbal communication score
Description: 1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).

Intervention type: OTHER
Intervention: Non-verbal communication score
Description: 1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
Study: NCT04847089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor imagery BCI training
Description: Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
Study: NCT05673304

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT anticipated boost
Description: 24 Gy in 3 fractions to the tumour
Study: NCT06085625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Surgery Survey
Description: Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-Surgery Surveys
Description: After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing.
Study: NCT04871919

Intervention type: DRUG
Intervention: Filgotinib
Description: Tablets are administered in accordance with the product label
Study: NCT04975230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Self-Management
Description: Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
Study: NCT05887284

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy (0.5 Gy)
Description: 12 times 0.5 Gy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: mock radiation treatment
Description: 6 times 0.0 Gy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: low dose radiotherapy (1.0 Gy)
Description: 6 times 1.0 Gy
Study: NCT05960955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV infusion,Specified dose on specified days
Study: NCT06099054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigtail catheter
Description: Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal tube
Description: Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
Study: NCT05816356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Oral administration of decitabine as a single dose to healthy male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Oral administration of decitabine as a single dose to healthy male subjects
Study: NCT04038203

Intervention type: DEVICE
Intervention: Resonance Raman Spectroscopy (RPS)
Description: RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
Study: NCT05879172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric tubular anastomotic device
Description: The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional anastomotic device
Description: Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
Study: NCT05876312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-038
Description: siRNA duplex oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-038
Description: siRNA duplex oligonucleotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05128344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMZ002 injectable solution, 0.5mg/mL
Description: Injectable solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin, oral
Description: Oral administration
Study: NCT05244642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: A humanized monoclonal immunoglobulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of Chemotherapy
Description: Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
Study: NCT04353804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Arm: Computerized Cognitive Rehabilitation
Description: Treatment Arm: Computerized Cognitive Rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control computer games
Description: Active Control computer games
Study: NCT05743517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Treatment
Description: This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Treatment
Description: This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Treatment
Description: This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Treatment
Description: This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
Study: NCT05058495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Lymphedema Self-Care Support Program
Description: The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
Study: NCT06451926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escape room game
Description: Educational escape rooms are live action games where teams use content knowledge to complete tasks and puzzles to reach a final goal, such as escaping from a room or completing a final puzzle
Study: NCT05101798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic acid Hydrochloride
Description: The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
Study: NCT06220786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: Low-level laser therapy ca. 72 Joules per cm2

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fake low-level laser therapy
Description: Identical laser pen without production of low-level laser therapy
Study: NCT05816356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrouridine
Description: Oral administration of Tetrahydrouridine as a single dose to healthy male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
Study: NCT05213052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical cream
Description: Topical cream applied to painful joint or muscle
Study: NCT05723393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: fascial plane injection guided by ultrasound
Study: NCT06559917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: life review
Description: After consenting, they will complete the first questionnaire before receiving the Happiness Ledger intervention via social media. Family members will have one week to organize photos, after which patients will share the meaning of the photos. This process will be recorded by the researcher and will last approximately 40 to 60 minutes. The researcher will then create a three-minute video using the photos, and the participating family members will assist in uploading the photos to the family LINE group as feedback to the subjects. The second questionnaire will then be completed.
Study: NCT06328829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Care
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT06433258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced TSSC curriculum
Description: In addition to the original TSSC curriculum participants will also be educated with the enhanced curriculum which includes components related to alcohol and social determinants of health needs) to promote cancer prevention through healthy lifestyles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original TSSC curriculum
Description: Participants will be educated with evidence-based modules focused on topics such as introduction to TSSC, physical activity, fruit and vegetable consumption, reduce sugar intake, diabetes, portion control, cancer, and high blood pressure.These modules are provided by community health workers who have been trained in the contents of the modules, as well as motivational interviewing techniques for delivering the modules.
Study: NCT05058495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standart lymphedema education
Description: The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standart lymphedema education
Description: The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
Study: NCT06328166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection with ES135
Description: Sono-guided injection with ES135 between carpal tunnel and median nerve

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection with placebo
Description: Sono-guided injection with placebo between carpal tunnel and median nerve
Study: NCT04855188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 540
Description: Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: YVOIRE volume plus
Description: Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
Study: NCT04521712

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
Description: All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
Study: NCT05623982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-038
Description: Administration by intravenous infusion
Study: NCT05312554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iris FIT™ PFO closure system
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
Study: NCT05745363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-target tyrosine kinase inhibitor
Study: NCT04137835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Showmotion
Description: Each healthy volunteers will wear sensors at the interested joint and do the measurement.
Study: NCT04890353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Study: NCT06563297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR\>100bpm and ABP\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
Study: NCT06201390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep consistency
Description: Participants will be asked to maintain a consistent bed- and wake-time.
Study: NCT04640246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBX-3400
Description: Autologous transfusion
Study: NCT04392999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarticular platelet rich plasma cervical facet injection
Description: Injection of PRP into the cervical facet joints.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Injection of corticosteroid into the cervical facet joints.
Study: NCT06073028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20-minute gait training
Description: All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20-minute gait training
Description: All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).